Medical news & information, drug approvals & FDA & NIH medical research news. Information on prescribing drugs, patient education, infectious diseases, the pharmaceutical industry & biomedical news.



Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    17-March-2001      
Issue 76 Next Update - 14:00 UTC 08:00 EST    18-March-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Proceed To Article In Today's Vidyya
cover
Advertisment for one of the only two prescription forms of niacin currently on the US Market.


Proceed To Article Simvastatin, Niacor ® Reduce Cardiac Events By 70% In Landmark Study
To date, medical guidelines have not recommended the use of niacin for the treatment of high cholesterol and triglycerides in diabetics because of concerns about the potential adverse effect on glycemic control. In September 2000, the American Medical Association published results of an Arterial Disease Multiple Intervention Trial (ADMIT) sub-study, which concluded that lipid-modifying doses of niacin have a minimal impact on glucose levels and can be safely prescribed for patients with diabetes as an alternative when statins or fibrates are inadequate or not tolerated. More...

Proceed To Article Prescribing Information: Slo-Niacin®
Slo-Niacin® is a member of the vitamin B-complex group (nicotinic acid, vitamin B-3) and is suggested as a dietary supplement. This product has the advantage of a slower release of niacin than conventional dosage forms. This may permit its use by those who do not tolerate immediate-release tablets. Niacin tablets in conjunction with Simvastatin show promise as a preventive against cardiovascular events. More...

Proceed To Article Prescribing Information: Niacor ®
The ADMIT study found that use of immediate-release Niacor ® helped reduce total cholesterol by 4%, LDL ("bad") cholesterol by 8% and triglycerides by 23%, while increasing HDL cholesterol levels by 29% -- with minimal impact on glycemic control. Niacin use resulted in a small but statistically significant increase in average glucose levels in participants with diabetes. The dropout rate for niacin therapy was similar for both diabetic and non-diabetic patients, with dropout rates of 23% and 16% respectively. Get the prescribing information for Niacor in today's issue of Vidyya. More...


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.

Medical news & information, drug approvals & FDA & NIH medical research news. Information on prescribing drugs, patient education, infectious diseases, the pharmaceutical industry & biomedical news.